<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128661</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441189</org_study_id>
    <secondary_id>NCI-04-C-N191</secondary_id>
    <secondary_id>NCI-590299/009</secondary_id>
    <secondary_id>GSK-590299/009</secondary_id>
    <nct_id>NCT00128661</nct_id>
    <nct_alias>NCT00344357</nct_alias>
  </id_info>
  <brief_title>Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants</brief_title>
  <official_title>A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing,
      or coming back. Vaccines may help the body build an effective immune response against human
      papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or
      cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective
      than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.

      PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how
      well it works compared to hepatitis A vaccine in preventing cervical intraepithelial
      neoplasia or cervical cancer in younger healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      •Demonstrate the efficacy of the candidate vaccine, human papillomavirus 16/18 (HPV 16/18) L1
      virus-like particle (VLP)/AS04 vaccine compared with control in preventing grade 2 or 3
      cervical intraepithelial neoplasia, adenocarcinoma in situ of the cervix, or invasive
      cervical cancer (CIN2+) associated with HPV 16 or HPV 18 cervical infection in younger
      healthy participants who are negative for HPV DNA by polymerase chain reaction (PCR) for the
      corresponding HPV type at months 0 and 6.

      Secondary

        -  Determine the duration of protection against HPV 16 or HPV 18 cervical infection in
           participants treated with the HPV 16/18 L1 VLP/AS04 vaccine.

        -  Determine the safety of this vaccine in these participants, regardless of their initial
           HPV 16/18 DNA status.

        -  Evaluate the efficacy of the candidate vaccine, HPV 16/18 L1 VLP/AS04 vaccine compared
           with control in preventing CIN2+ associated with any oncogenic HPV type cervical
           infection in participants who are negative for HPV DNA by PCR for the corresponding HPV
           type at months 0 and 6.

        -  Compare the efficacy of the candidate vaccine with control in preventing CIN2+
           associated with HPV 16 or HPV 18 cervical infection, detected within the lesional
           component of the cervical tissue specimen by PCR, in participants who are negative for
           HPV DNA by PCR for the corresponding HPV type at months 0 and 6 and by enzyme-linked
           immunosorbent assay (ELISA) at month 0.

        -  Compare the efficacy of the candidate vaccine with control in preventing persistent HPV
           16 or HPV 18 cervical infection in these participants.

        -  Determine the immunogenicity of HPV 16/18 L1 VLP/AS04 vaccine by ELISA and V5/J4
           monoclonal antibody inhibition enzyme immunoassay in the first 600 participants
           randomized to receive HPV 16/18 L1 VLP/AS04 vaccine.

      OUTLINE: This is a randomized, controlled, double-blind, parallel-group study. Participants
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Participants receive human papillomavirus 16/18 L1 virus-like particle/AS04
           vaccine intramuscularly (IM) once in months 0, 1, and 6.

        -  Arm II: Participants receive hepatitis A vaccine (Havrix®) IM once in months 0, 1, and
           6.

      After completion of study treatment, participants are followed at 6 months and then at least
      annually for 3 years.

      PROJECTED ACCRUAL: Approximately 7,500 participants will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.</measure>
    <time_frame>From Month 6 up to Month 48</time_frame>
    <description>CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer.
Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained.
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cervical Infection With HPV16 or HPV18.</measure>
    <time_frame>From Month 6 up to Month 48</time_frame>
    <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type</measure>
    <time_frame>From Month 6 up to Month 48</time_frame>
    <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 detected by polymerase chain reaction (PRC) in the preceding cervical cytology specimen.
Note: The assay did not distinguish between HPV types 68 and 73.
CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases</measure>
    <time_frame>From Month 6 up to Month 48</time_frame>
    <description>Persistent incident HPV-16 and /or HPV-18 cervical infection had to fulfil the following criteria: first detection after the 6-month visit, 2 same type HPV positive (by PCR) test results 10+ months apart, and no intervening HPV negative tests for the corresponding type.
Persistent HPV16 or HPV18 cervical infection = detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples from all consecutive evaluations over approximately 12 months.
Subjects were HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.</measure>
    <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative subjects = antibody concentration below 8 ELISA Units per millilitre (EL.U/mL) prior to vaccination.
Seropositive subjects=antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immunogenicity subcohort = subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort</measure>
    <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohortby Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 7 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)</measure>
    <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 41 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 41 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)</measure>
    <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 110 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 110 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>Within 60 minutes after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</measure>
    <time_frame>Within 60 minutes after vaccination</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.</measure>
    <time_frame>From Day 3 to Day 6 after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.</measure>
    <time_frame>From Day 3 to Day 6 after vaccination</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With All Possible Pregnancy Outcomes</measure>
    <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
    <description>The range of possible pregnancy outcomes was: Pregnancy loss, Pregnancy resolved alive, and Unresolved pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cervical Infection With HPV16 or HPV18.</measure>
    <time_frame>During the first year of follow-up period</time_frame>
    <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cervical Infection With HPV16 or HPV18.</measure>
    <time_frame>During the second year of follow-up period</time_frame>
    <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cervical Infection With HPV16 or HPV18.</measure>
    <time_frame>During the third year of follow-up period</time_frame>
    <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cervical Infection With HPV16 or HPV18.</measure>
    <time_frame>From the fourth year follow-up period</time_frame>
    <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</measure>
    <time_frame>within 30 days (Days 0-29) after vaccination</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7466</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine</intervention_name>
    <description>Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule</description>
    <arm_group_label>Cervarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepatitis A inactivated virus vaccine</intervention_name>
    <description>Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule</description>
    <arm_group_label>Havrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        •Healthy participants

          -  Deemed to be in good general health by history and physical examination

             •Resident of Guanacaste Province of Costa Rica and surrounding areas

          -  Must remain a resident for ≥ 6 months after the first study vaccination

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 25

        Performance status

        •Not specified

        Life expectancy

        •Not specified

        Hematopoietic

        •Not specified

        Hepatic

          -  No history of chronic hepatitis requiring treatment

          -  No acute or chronic clinically significant hepatic function abnormality by physical
             examination or laboratory findings

          -  No known history of hepatitis A infection

        Renal

          -  No history of kidney disease requiring treatment

          -  No acute or chronic clinically significant kidney function abnormality by physical
             examination or laboratory findings

        Cardiovascular

          -  No acute or chronic clinically significant cardiovascular function abnormality by
             physical examination or laboratory findings Pulmonary

          -  No acute or chronic clinically significant pulmonary function abnormality by physical
             examination or laboratory findings Immunology

          -  No history of allergic disease

          -  No history of autoimmune disorder requiring treatment

          -  No history of allergic reaction (e.g., difficulty breathing) to any vaccine

          -  No suspected allergy or reaction likely to be exacerbated by a component of the study
             vaccines (e.g., 2-phenoxyethanol or neomycin)

          -  No hypersensitivity to latex

          -  No diagnosis or suspicion of any immunodeficient condition by medical history or
             physical examination Other

          -  Not pregnant or nursing

             ◦No delivery within the past 3 months

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for 30 days before, during, and for
             60 days after completion of study treatment

          -  Able to speak or understand Spanish

          -  Mentally competent

          -  Able to undergo pelvic exam (i.e., no heavy bleeding [menstruation or otherwise] or
             heavy vaginal discharge)

          -  No history of cancer requiring treatment

          -  No history of diabetes requiring treatment

          -  No history of other chronic conditions requiring treatment

          -  No acute or chronic clinically significant neurologic function abnormality by physical
             examination or laboratory findings

          -  No other acute disease

          -  No fever ≥ 37.5º C

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 6 months since prior chronic administration (i.e., &gt; 14 days) of
             immune-modulating drugs

          -  More than 90 days since prior immunoglobulins

          -  More than 30 days since prior and no other concurrent investigational or
             non-registered vaccines

          -  More than 30 days since prior registered vaccines

          -  More than 8 days since prior routine meningococcal, hepatitis B, influenza, or
             diphtheria/tetanus vaccine

          -  No prior vaccination against hepatitis A

          -  No prior vaccination against human papillomavirus

          -  No prior monophosphoryl lipid A or AS04 adjuvant

        Chemotherapy

        •Not specified

        Endocrine therapy

          -  More than 6 months since prior chronic administration (i.e., &gt; 14 days) of
             corticosteroids (e.g., ≥ 0.5 mg/kg/day of prednisone or equivalent)

          -  Concurrent inhaled or topical steroids allowed

        Radiotherapy

        •Not specified

        Surgery

        •No prior hysterectomy

        Other

          -  More than 6 months since prior chronic administration (i.e., &gt; 14 days) of
             immunosuppressants

          -  More than 30 days since prior and no other concurrent investigational or
             non-registered drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proyecto Epidemiologico Guanacaste</name>
      <address>
        <city>Liberia</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <reference>
    <citation>Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319. Epub 2011 Sep 9.</citation>
    <PMID>21908768</PMID>
  </reference>
  <reference>
    <citation>Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011 Mar 3;29(11):2011-4. doi: 10.1016/j.vaccine.2011.01.001. Epub 2011 Jan 15.</citation>
    <PMID>21241731</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <results_first_submitted>December 15, 2011</results_first_submitted>
  <results_first_submitted_qc>April 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical intraepithelial neoplasia grade 2</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Solicited symptoms were collected for 3730 and 3740 subjects instead of the 3727 and 3739 subjects who were randomized in the study in the Cervarix and the Havrix groups, respectively. These 4 sujects received both vaccines and were included in the denominator of both arm based on the actual vaccine type administered.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3727"/>
                <participants group_id="P2" count="3739"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3453"/>
                <participants group_id="P2" count="3481"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="258"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3727"/>
            <count group_id="B2" value="3739"/>
            <count group_id="B3" value="7466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="2.3"/>
                    <measurement group_id="B2" value="21.1" spread="2.3"/>
                    <measurement group_id="B3" value="21.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3727"/>
                    <measurement group_id="B2" value="3739"/>
                    <measurement group_id="B3" value="7466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.</title>
        <description>CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer.
Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained.
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type.</description>
        <time_frame>From Month 6 up to Month 48</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.</title>
          <description>CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer.
Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained.
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type.</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2635"/>
                <count group_id="O2" value="2677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Associated CIN2+ (N=2464;2452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Associated CIN2+ (N=2567; 2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Associated CIN2+ (N=2635;2677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cervical Infection With HPV16 or HPV18.</title>
        <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>From Month 6 up to Month 48</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cervical Infection With HPV16 or HPV18.</title>
          <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2635"/>
                <count group_id="O2" value="2677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Cervical Infection (N=2464;2452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Cervical Infection (N=2567;2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Cervical Infection (N=2635;2677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type</title>
        <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 detected by polymerase chain reaction (PRC) in the preceding cervical cytology specimen.
Note: The assay did not distinguish between HPV types 68 and 73.
CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>From Month 6 up to Month 48</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type</title>
          <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 detected by polymerase chain reaction (PRC) in the preceding cervical cytology specimen.
Note: The assay did not distinguish between HPV types 68 and 73.
CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer
Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2643"/>
                <count group_id="O2" value="2697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Associated CIN2+ (N=2464;2452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Associated CIN2+ (N=2567,2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV31 Associated CIN2+ (N=2525;2546)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV33 Associated CIN2+ (N=2596;2645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV35 Associated CIN2+ (N=2593;2631)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV39 Associated CIN2+ (N=2528;2581)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV45 Associated CIN2+ (N=2573;2622)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV51 Associated CIN2+ (N=2453;2539)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV52 Associated CIN2+ (N=2456;2505)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV56 Associated CIN2+ (N=2524;2564)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV58 Associated CIN2+ (N=2551;2595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV59 Associated CIN2+ (N=2576;2637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV68 and/or 73 Associated CIN2+ (N=2519;2576)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non 16/18 Onco HPV Associated CIN2+ (N=2643;2697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Oncogenic HPV Associated CIN2+ (N=2643;2697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases</title>
        <description>Persistent incident HPV-16 and /or HPV-18 cervical infection had to fulfil the following criteria: first detection after the 6-month visit, 2 same type HPV positive (by PCR) test results 10+ months apart, and no intervening HPV negative tests for the corresponding type.
Persistent HPV16 or HPV18 cervical infection = detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples from all consecutive evaluations over approximately 12 months.
Subjects were HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type.</description>
        <time_frame>From Month 6 up to Month 48</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases</title>
          <description>Persistent incident HPV-16 and /or HPV-18 cervical infection had to fulfil the following criteria: first detection after the 6-month visit, 2 same type HPV positive (by PCR) test results 10+ months apart, and no intervening HPV negative tests for the corresponding type.
Persistent HPV16 or HPV18 cervical infection = detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples from all consecutive evaluations over approximately 12 months.
Subjects were HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type.</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2635"/>
                <count group_id="O2" value="2677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Persistent HPV16 Infection (N=2464,2452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent HPV18 Infection (N=2567;2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent HPV16 and/or 18 Infection (N=2635;2677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.</title>
        <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative subjects = antibody concentration below 8 ELISA Units per millilitre (EL.U/mL) prior to vaccination.
Seropositive subjects=antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immunogenicity subcohort = subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7)</description>
        <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
        <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.</title>
          <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative subjects = antibody concentration below 8 ELISA Units per millilitre (EL.U/mL) prior to vaccination.
Seropositive subjects=antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immunogenicity subcohort = subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7)</description>
          <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 [before vaccination] (N=194;156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="5.7" upper_limit="7.8"/>
                    <measurement group_id="O2" value="8.2" lower_limit="6.7" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 1] (N=196,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646.6" lower_limit="549.3" upper_limit="761.1"/>
                    <measurement group_id="O2" value="7.9" lower_limit="6.5" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 6] (N=195,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.5" lower_limit="668.3" upper_limit="890.7"/>
                    <measurement group_id="O2" value="8.4" lower_limit="6.9" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 7] (N=195,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3261" lower_limit="2959" upper_limit="3595"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.9" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 12] (N=182,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2090" lower_limit="1822" upper_limit="2398"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.7" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 18] (N=25,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1045" lower_limit="776.0" upper_limit="1408"/>
                    <measurement group_id="O2" value="10.4" lower_limit="4.8" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 24] (N=175,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1486" lower_limit="1293" upper_limit="1709"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 30] (N=19,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1070" lower_limit="747.5" upper_limit="1532"/>
                    <measurement group_id="O2" value="11.9" lower_limit="5.1" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 36] (N=163,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1256" lower_limit="1080" upper_limit="1461"/>
                    <measurement group_id="O2" value="9.0" lower_limit="7.4" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 42] (N=22,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1259" lower_limit="879.4" upper_limit="1802"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.0" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 48] (N=172,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1155" lower_limit="1009" upper_limit="1322"/>
                    <measurement group_id="O2" value="9.5" lower_limit="7.7" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort</title>
        <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohortby Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 7 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
        <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
        <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort</title>
          <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohortby Enzyme linked immunosorbent assay (ELISA) and expressed as geometric mean titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 7 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
          <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-18 [before vaccination] (N=200;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.8" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.2" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 1] (N=203;170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.7" lower_limit="322.8" upper_limit="430.3"/>
                    <measurement group_id="O2" value="6.4" lower_limit="5.4" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 6] (N=203;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532.2" lower_limit="467.5" upper_limit="605.9"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 7] (N=202;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3276" lower_limit="3001" upper_limit="3576"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.7" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 12] (N=190;166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1082" lower_limit="942.0" upper_limit="1242"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.7" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 18] (N=28;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502.4" lower_limit="339.1" upper_limit="744.5"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.8" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 24] (N=178;150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="633.0" lower_limit="551.5" upper_limit="726.6"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.6" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 30] (N=17;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.8" lower_limit="257.8" upper_limit="632.5"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.8" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 36] (N=168;145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519.7" lower_limit="449.3" upper_limit="601.1"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 42] (N=25;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582.4" lower_limit="422.9" upper_limit="801.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.6" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 48] (N=179;149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.1" lower_limit="411.2" upper_limit="537.4"/>
                    <measurement group_id="O2" value="6.6" lower_limit="5.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)</title>
        <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 41 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 41 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
        <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
        <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)</title>
          <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 41 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 41 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
          <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 [before vaccination] (N=196;158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="20.5" upper_limit="21.8"/>
                    <measurement group_id="O2" value="21.4" lower_limit="20.6" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 1] (N=182;155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="48.3" upper_limit="70.8"/>
                    <measurement group_id="O2" value="21.5" lower_limit="20.7" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 6] (N=189;156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="70.3" upper_limit="93.1"/>
                    <measurement group_id="O2" value="21.5" lower_limit="20.6" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 7] (N=193;158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1047" lower_limit="926.3" upper_limit="1183"/>
                    <measurement group_id="O2" value="21.4" lower_limit="20.6" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 12] (N=175;146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.4" lower_limit="253.7" upper_limit="334.8"/>
                    <measurement group_id="O2" value="22.6" lower_limit="20.8" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 18] (N=24;17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.6" lower_limit="83.2" upper_limit="163.3"/>
                    <measurement group_id="O2" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 24] (N=169;138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.6" lower_limit="163.0" upper_limit="209.1"/>
                    <measurement group_id="O2" value="21.4" lower_limit="20.6" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 30] (N=18;15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.4" lower_limit="78.7" upper_limit="160.6"/>
                    <measurement group_id="O2" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 36] (N=162;132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.7" lower_limit="122.5" upper_limit="159.5"/>
                    <measurement group_id="O2" value="20.8" lower_limit="20.2" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 42] (N=22;18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.9" lower_limit="89.9" upper_limit="179.1"/>
                    <measurement group_id="O2" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 [at Month 48] (N=168;133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" lower_limit="115.5" upper_limit="150.5"/>
                    <measurement group_id="O2" value="21.0" lower_limit="20.4" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)</title>
        <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 110 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 110 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
        <time_frame>Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48</time_frame>
        <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)</title>
          <description>Titers were assessed for the 600 subjects enrolled into the immunogenicity subcohort by Inhibition Enzyme Immunoassay (EIA) and expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects=antibody concentration below 110 EL.U/mL prior to vaccination.
Seropositive (Sero+) subjects=antibody concentration equal to or above 110 EL.U/mL prior to vaccination.
Immunogenicity subcohort=subset of 600 subjects from the 2 groups of the ATP cohort: subjects attended 1 extra clinic visit approximately 1 month (30 to 60 days) after the last dose was administered (Month 7).</description>
          <population>The ATP cohort for immunogenicity included subjects who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and during the 48-month follow-up period, who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6) and for whom immunogenicity results were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-18 [before vaccination] (N=203;176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="55.7" lower_limit="54.7" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 1] (N=197;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="88.0" upper_limit="111.5"/>
                    <measurement group_id="O2" value="55.3" lower_limit="54.7" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 6] (N=195;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.4" lower_limit="100.2" upper_limit="123.9"/>
                    <measurement group_id="O2" value="55.4" lower_limit="54.6" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 7] (N=198;176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823.6" lower_limit="737.7" upper_limit="919.5"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 12] (N=182;166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.1" lower_limit="203.2" upper_limit="262.7"/>
                    <measurement group_id="O2" value="56.7" lower_limit="54.7" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 18] (N=28;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.8" lower_limit="89.5" upper_limit="165.8"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 24] (N=170;154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.8" lower_limit="123.8" upper_limit="160.2"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 30] (N=17;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="67.6" upper_limit="118.7"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 36] (N=167;145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.9" lower_limit="96.0" upper_limit="121.2"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 42] (N=25;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.3" lower_limit="80.3" upper_limit="132.9"/>
                    <measurement group_id="O2" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 [at Month 48 (N=179;150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="87.7" upper_limit="107.0"/>
                    <measurement group_id="O2" value="56.7" lower_limit="54.0" upper_limit="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
        <time_frame>Within 60 minutes after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3730"/>
                <count group_id="O2" value="3740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1627"/>
                    <measurement group_id="O2" value="1610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544"/>
                    <measurement group_id="O2" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
        <time_frame>Within 60 minutes after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3730"/>
                <count group_id="O2" value="3740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512"/>
                    <measurement group_id="O2" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="714"/>
                    <measurement group_id="O2" value="718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) &gt;= 37.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472"/>
                    <measurement group_id="O2" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) &gt; 39.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
        <time_frame>From Day 3 to Day 6 after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
        <time_frame>From Day 3 to Day 6 after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal everyday activities as assessed by inability to attend work or school and which necessitated the administration of corrective therapy.Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = oral temperature &gt; 39.0°C.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) &gt;= 37.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) &gt; 39.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
        <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3727"/>
                <count group_id="O2" value="3739"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912"/>
                    <measurement group_id="O2" value="891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3727"/>
                <count group_id="O2" value="3739"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3228"/>
                    <measurement group_id="O2" value="3254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With All Possible Pregnancy Outcomes</title>
        <description>The range of possible pregnancy outcomes was: Pregnancy loss, Pregnancy resolved alive, and Unresolved pregnancy.</description>
        <time_frame>During the entire study period (From Month 0 up to Month 48).</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on all pregnant subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With All Possible Pregnancy Outcomes</title>
          <description>The range of possible pregnancy outcomes was: Pregnancy loss, Pregnancy resolved alive, and Unresolved pregnancy.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on all pregnant subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2123"/>
                <count group_id="O2" value="2129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pregnancy loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy resolved alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1756"/>
                    <measurement group_id="O2" value="1766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unresolved pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cervical Infection With HPV16 or HPV18.</title>
        <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>During the first year of follow-up period</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cervical Infection With HPV16 or HPV18.</title>
          <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2380"/>
                <count group_id="O2" value="2420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Cervical Infection (N=2242;2232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Cervical Infection (N=2330;2347)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Cervical Infection (N=2380;2420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cervical Infection With HPV16 or HPV18.</title>
        <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>During the second year of follow-up period</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cervical Infection With HPV16 or HPV18.</title>
          <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2313"/>
                <count group_id="O2" value="2349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Cervical Infection (N=2170;2176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Cervical Infection (N=2269;2307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Cervical Infection (N=2313;2349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cervical Infection With HPV16 or HPV18.</title>
        <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>During the third year of follow-up period</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cervical Infection With HPV16 or HPV18.</title>
          <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2232"/>
                <count group_id="O2" value="2196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Cervical Infection (N=2097;2026)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Cervical Infection (N=2200;2196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Cervical Infection (N=2236;2166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cervical Infection With HPV16 or HPV18.</title>
        <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
        <time_frame>From the fourth year follow-up period</time_frame>
        <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cervical Infection With HPV16 or HPV18.</title>
          <description>Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) (by PCR) at Month 0 and Month 6 for the corresponding HPV-type</description>
          <population>The According-To-Protocol (ATP) cohort for efficacy included subjects with efficacy data available, who received 3 doses of vaccine, who were HPV DNA- for the corresponding type at enrollment and at the time of administration of the 3rd dose (Month 6) and who did not have a biopsy or treatment during the vaccination phase (prior to the Month 6).</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2421"/>
                <count group_id="O2" value="2325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 Cervical Infection (N=2277;2139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 Cervical Infection (N=2389;2325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 and/or 18 Cervical Infection (N=2421;2261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>within 30 days (Days 0-29) after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects with at least 1 vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3727"/>
                <count group_id="O2" value="3739"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1638"/>
                    <measurement group_id="O2" value="1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs: within 60 minutes after vaccination for all subjects; From Day 3 to Day 6 post-vaccination in the subset. SAEs: From Month 0 up to Month 48. Unsolicited AEs: From Month 0 up to Month 48 and Within 30 days (Days 0-29) after vaccination</time_frame>
      <desc>Solicited AEs were collected and tabulated for all subjects and for a 10% random subset of participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="912" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="891" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Anaemia haemolytic autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital flat feet</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Multiple congenital abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye degenerative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Peritoneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tooth ankylosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tooth development disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tooth malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Eye complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Rhesus incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bartholin’s abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Parametritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Mastitis postpartum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Venom poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Placental neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vulval neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Uterine hypotonus</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Failed induction of labour</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Obstructed labour</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abnormal product of conception</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Multiple pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Placenta praevia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foetal disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Large for dates baby</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Transverse presentation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Umbilical cord abnormality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion complicated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Polyhydramnios</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Traumatic delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Umbilical cord prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion incomplete complicated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete complicated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Foetal malposition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Intrapartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma obstetric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Placental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Postpartum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Previous caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Twin pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Uterine inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Genital disorder female</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bartholin’s cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Haematocolpos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Haematosalpinx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Ovulation pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Polymenorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Granuloma skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Sexual abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1627" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="1610" subjects_at_risk="3740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="263" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="1627" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="1610" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="544" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="501" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="512" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="502" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="714" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="718" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Within 60 minutes after vaccination.</description>
                <counts group_id="E1" subjects_affected="472" subjects_at_risk="3730"/>
                <counts group_id="E2" subjects_affected="477" subjects_at_risk="3740"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="380"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Within 30 days (Days 0-29) after vaccination</description>
                <counts group_id="E1" subjects_affected="263" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="903" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="950" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="709" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="763" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="714" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="678" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="555" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="565" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="327" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Within 30 days (Days 0-29) after vaccination</description>
                <counts group_id="E1" subjects_affected="355" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Within 30 days (Days 0-29) after vaccination</description>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="3739"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="315" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From Month 0 up to Month 48</description>
                <counts group_id="E1" subjects_affected="1021" subjects_at_risk="3727"/>
                <counts group_id="E2" subjects_affected="1011" subjects_at_risk="3739"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The following analysis &quot;occurence of histopathologically confirmed CIN2+ cases associated with HPV16 or HPV18 infection was not performed, in accordance with the Statistical Analysis Plan submitted to the FDA.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

